BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, which sees “a relatively clean setup” for growth at the high end of the peer group being balanced by a premium multiple and limited late-stage pipeline catalysts, is shifting its valuation basis to its FY27 estimates.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Hold Rating: Balancing Growth Opportunities with Valuation and Pipeline Challenges
- AbbVie’s New Study on Parkinson’s Treatment: What Investors Need to Know
- AbbVie’s Pediatric Kidney Disease Study Update: Implications for Investors
- AbbVie’s Venetoclax Study for AML: Key Insights for Investors
- AbbVie’s Phase III CLL Study: A Potential Game-Changer in Cancer Treatment